… ProQR Therapeutics Virtual R&D Event 2023 ProQR will host a virtual R&D event on Wednesday, March 29, … under “Events” in the “Investors & Media” section of ProQR’s website at www.proqr.com/events . The presentation is …
… ProQR Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor conference call and … the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am …
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval
… ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives …